1	~			D	ocket Number	OP/4-3	1881A			
*	FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10									
2	JC51	EL 913014714 US Express Mail Label Number			February 21, 2002 Date of Deposit					
/21/02	·	Assistant Commissione Box Patent Application Washington, DC 20231	r for Patents							PTO
	UTILITY PATENT APPLICATION TRANSMITTAL AND FEE									
Ę	Transmitted herewith for filing under 37 CFR §1.53(b) is the utility patent application of								68 L	
	Applicant	(or identifier): B	RAZZELL ET	AL.						jce
	Title:	Title: METHOD OF TREATING OCULAR NEOVASCULARIZAT							ATION	l
502E	Enclosed are:									
and the limb lend only limb lend only limb limb only limb lend on the limb lend on	 Specification (Including Claims and Abstract) - 35 pages Drawings - sheets Executed Declaration and Power of Attorney (original or copy) Microfiche Computer Program (appendix) Nucleotide and/or Amino Acid Sequence Submission Computer Readable Copy Paper Copy Statement Verifying Identity of Above Copies Preliminary Amendment Assignment Papers (Cover Sheet & Document(s)) English Translation of Information Disclosure Statement Certified Copy of Priority Document(s) Return Receipt Postcard Other: Unexecuted Declaration, Application Data Sheet 									
	Filing fee calculation: Before calculating the filing fee, please enter the enclosed Preliminary Amendment. Before calculating the filing fee, please cancel claims									
	Basic Filing Fee Multiple Dependent Claim Fee (\$ 280)							\$	740	
	Foreign Language Surcharge (\$ 900)								\$	
		For	Number Filed		Number Extra		Rate			
	Extra Claims	Total Claims	42	-20	22	x	\$ 18	=	\$	396
		Independent	1	-3	0	х	\$ 84	=	\$	

1,136

TOTAL FILING FEE \$

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$1,136. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027

Date: February 21, 2002

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Respectfully submitted,

David E. Wildman

Attorney for Applicants Reg. No. 40,226

Tel. No. (908) 522-6946

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10 EL 913014714 US February 21, 2002 Express Mail Label Number Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BRAZZELL ET AL.

APPLICATION NO: Not Yet Assigned

FILED: February 21, 2002

FOR: METHOD OF TREATING OCULAR NEOVASCULARIZATION

Assistant Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING INCLUDING STATEMENT OF VERIFICATION

Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027 (908) 522-6946

Date: February 21, 2002

David E. Wildman Attorney for Applicants

Reg. No. 40,226